Advertisement

Topics

FDA orphan status granted to AZ's neurofibromatosis type 1 drug

04:56 EST 15 Feb 2018 | SmartBrief

AstraZeneca's neurofibromatosis type 1 drug candidate selumetinib received orphan status from the FDA.  -More

Original Article: FDA orphan status granted to AZ's neurofibromatosis type 1 drug

NEXT ARTICLE

More From BioPortfolio on "FDA orphan status granted to AZ's neurofibromatosis type 1 drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...